InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1 [TheStreet.com]
Telomir Pharmaceuticals, Inc. (TELO)
Company Research
Source: TheStreet.com
New Drug application to the FDA for Telomir-1 (Telomir-Zn) targeting advanced and metastatic triple-negative breast cancer, supported by preclinical efficacy and safety data demonstrating tumor growth reduction and favorable tolerability. Pending IND clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating the oral therapy, with a focus on safety, dose optimization and early signs of antitumor activity, as it advances a novel epigenetic approach aimed at addressing significant unmet need in aggressive breast cancer. To view the full press release, visit https://ibn.fm/CgUik About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The Company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving
Show less
Read more
Impact Snapshot
Event Time:
TELO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TELO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TELO alerts
High impacting Telomir Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TELO
News
- Telomir Pharmaceuticals (TELO) was upgraded by Zacks Research to "hold".MarketBeat
- Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TELO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Telomir Pharmaceuticals (NASDAQ:TELO) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
TELO
Sec Filings
- 3/31/26 - Form 8-K
- 3/31/26 - Form 8-K
- 3/27/26 - Form 8-K
- TELO's page on the SEC website